The startup’s AI platform uses AI algorithms to automatically detect abnormalities and diseases in medical images, reducing patient misdiagnosis and increasing radiologists’ productivity
The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
Subscribe To Our Newsletter & Stay Updated
